- 155 Actual Exam Questions
- Compatible with all Devices
- Printable Format
- No Download Limits
- 90 Days Free Updates
Get All North American Pharmacist Licensure Examination Exam Questions with Validated Answers
| Vendor: | NABP |
|---|---|
| Exam Code: | NAPLEX |
| Exam Name: | North American Pharmacist Licensure Examination |
| Exam Questions: | 155 |
| Last Updated: | March 8, 2026 |
| Related Certifications: | North American Pharmacist Licensure |
| Exam Tags: | PharmacistsPharmacy TechniciansClinical Pharmacists |
Looking for a hassle-free way to pass the NABP North American Pharmacist Licensure Examination exam? DumpsProvider provides the most reliable Dumps Questions and Answers, designed by NABP certified experts to help you succeed in record time. Available in both PDF and Online Practice Test formats, our study materials cover every major exam topic, making it possible for you to pass potentially within just one day!
DumpsProvider is a leading provider of high-quality exam dumps, trusted by professionals worldwide. Our NABP NAPLEX exam questions give you the knowledge and confidence needed to succeed on the first attempt.
Train with our NABP NAPLEX exam practice tests, which simulate the actual exam environment. This real-test experience helps you get familiar with the format and timing of the exam, ensuring you're 100% prepared for exam day.
Your success is our commitment! That's why DumpsProvider offers a 100% money-back guarantee. If you don’t pass the NABP NAPLEX exam, we’ll refund your payment within 24 hours no questions asked.
Don’t waste time with unreliable exam prep resources. Get started with DumpsProvider’s NABP NAPLEX exam dumps today and achieve your certification effortlessly!
Which of the following is/are appropriate for pseudomonas skin/soft tissue infections?
Ceftaroline covers MRSA, but it does not cover pseudomonas. Ertapenem does not cover pseudomonas. Cefazolin does not cover MRSA nor Pseudomonas. Cefepime has pseudomonas coverage. Vancomycin does not cover gram negative bacteria.
Which of the following medication may increase LDL?
LDL can be elevated by diuretics, cyclosporine, glucocorticoids, and amiodarone.
http://circ.ahajournals.org/content/129/25_suppl_2/S1
Which of the following beta-blocker is NOT proven to reduce mortality in patients with Systolic CHF?
Nadolol is not proven to reduce mortality in patients with systolic CHF. The efficacy of nadolol in HF has not been determined. For patients taking nadolol, it should be used with caution in those with compensated heart failure and patients should be monitored for a worsening of the condition. Bisoprolol, carvedilol, and sustained- release metoprolol succinate are the beta-blockers that have been proven to reduce mortality in patients with systolic CHF. These 3 beta-blockers have been effective in reducing the risk of death in patients with chronic HFrEF. Other beta-blockers were found to be less effective. Bucindolol did not exhibit uniform effectiveness across different populations. Metoprolol tartrate was found to be less effective in HF clinical trials.
http://circ.ahajournals.org/content/128/16/e240
You get an order for 5% amino acid 15% dextrose premixed parenteral nutrition solution, 2 L at 83mls/hr. Your pharmacy technician tells you there is manufacture's backorder on those. How many ml of 20% dextrose would you need to provide the same amount of dextrose in 24 hrs?
15% dextrose = 15gm/100ml = 300gm/2000ml. Patient needs 300gm. 300gm/Xml = 20gm/100ml = 1500ml
In the US Nurses' Health Study (NHS) cohort study, where they looked at association of regular aspirin use (two 325 mg tablets/week) and colorectal cancer in 82,911 women found (RR, 0.77; 95% CI, 0.67--0.88) over 20 years of follow-up.
In an another analysis of the NHS, regular aspirin use, investigator also found (hazard ratio [HR]=0.72, 95% CI 0.56--0.92), what does this say about the mortality from colorectal cancer? How can this data best be interpreted?
Relative risk can be stated as 0.77 times as likely or 0.77 times the risk, but it could also be illustrated as a relative risk reduction and stated as a 23% risk reduction or 23% lower risk by taking the medication.
https://www.ncbi.nlm.nih.gov/books/NBK63647/
Security & Privacy
Satisfied Customers
Committed Service
Money Back Guranteed